Author: marypittmann8

Peijia Medical Limited (“Peijia Medical” or the “Company”, together with its subsidiaries, the “Group”, stock code: 9996), a leading domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets in China, announced its interim results for the six months ended June 30, 2022 (the “Period”).Performance Summary:— Revenue was RMB118.8 million, representing an increase of 129.8% from the same period of 2021.— Gross profit (excluding the amortization cost from purchase price allocation) was RMB87.6 million, representing an increase of 133.5% from the same period in 2021, and gross margin (excluding the amortization cost from purchase price allocation) ... Read more